Patrick G. Harran
Oprichter bij Joyant Pharmaceuticals, Inc.
Profiel
Patrick G.
Harran is the founder of Joyant Pharmaceuticals, Inc. (founded in 2004) and Diazon Pharmaceuticals, Inc. (founded in 2013).
Currently, he is a Member at Alfred P.
Sloan Foundation.
Previously, he worked as a Professor at The University of Texas at Austin.
He received his doctorate degree from Yale University in 1995 and his undergraduate degree from Skidmore College.
Actieve functies van Patrick G. Harran
Bedrijven | Functie | Begin |
---|---|---|
Joyant Pharmaceuticals, Inc.
Joyant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Their core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of its company is on the development of unique chemical entities that operate by new cellular mechanisms. Its understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. They intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics. | Oprichter | 16-04-2010 |
Alfred P. Sloan Foundation
Alfred P. Sloan Foundation Miscellaneous Commercial ServicesCommercial Services Alfred P Sloan Foundation operates a non-profit organization. Its programs and interests are divided into five main areas as science & technology, standard of living & economic performance, education &careers in science & technology, selected national issues and the civic program. The foundation was established in 1934 and is headquartered in New York | Corporate Officer/Principal | 20-04-2010 |
Eerdere bekende functies van Patrick G. Harran
Bedrijven | Functie | Einde |
---|---|---|
Diazon Pharmaceuticals, Inc.
Diazon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Diazon Pharmaceuticals, Inc. engages in the development of the onco-therapeutic DZ-2384 that targets a proven therapeutic pathway in oncology. The company was founded by Anne Roulston, Gordon Shore and Patrick Harran in 2013 and is headquartered in Montreal, Canada. | Oprichter | - |
The University of Texas at Austin | Corporate Officer/Principal | - |
Opleiding van Patrick G. Harran
Yale University | Doctorate Degree |
Skidmore College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 3 |
---|---|
Joyant Pharmaceuticals, Inc.
Joyant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Their core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of its company is on the development of unique chemical entities that operate by new cellular mechanisms. Its understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. They intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics. | Health Technology |
Alfred P. Sloan Foundation
Alfred P. Sloan Foundation Miscellaneous Commercial ServicesCommercial Services Alfred P Sloan Foundation operates a non-profit organization. Its programs and interests are divided into five main areas as science & technology, standard of living & economic performance, education &careers in science & technology, selected national issues and the civic program. The foundation was established in 1934 and is headquartered in New York | Commercial Services |
Diazon Pharmaceuticals, Inc.
Diazon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Diazon Pharmaceuticals, Inc. engages in the development of the onco-therapeutic DZ-2384 that targets a proven therapeutic pathway in oncology. The company was founded by Anne Roulston, Gordon Shore and Patrick Harran in 2013 and is headquartered in Montreal, Canada. | Health Technology |